Printer Friendly

GI Dynamics Presents Study Results Comparing Gastric Bypass and EndoBarrier Therapy.

M2 PHARMA-May 19, 2015-GI Dynamics Presents Study Results Comparing Gastric Bypass and EndoBarrier Therapy

(C)2015 M2 COMMUNICATIONS

Data showing improvement in glucose metabolism following treatment with US-based medical device maker GI Dynamics, Inc.'s (ASX: GID) EndoBarrier Therapy (duodenal-jejunal bypass liner or DJBL) suggests that the treatment comes significantly close to improvement achieved with gastric bypass surgery in obese patients with type 2 diabetes, the company said on Tuesday.

In a poster titled, 'Improvement in Glucose Metabolism after Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Duodenojejunal Bypass,' Dr. Jurgen Stein, Department of Gastroenterology and Clinical Nutrition, Hospital Sachsenhausen, Frankfurt, Germany, presented these findings at the American Gastroenterological Association's annual Digestive Disease Week meeting in Washington, DC.

According to the company, this is the first study comparing the improvement in glucose metabolism following gastric bypass surgery, considered the 'gold standard' of metabolic surgery, to the less invasive endoscopic placement of the EndoBarrier device.

Preliminary data demonstrate that both procedures have a similar impact on diabetes remission and significant impact on body weight: RYGB (? HbA1c, -1.1%, ? bw 28.2 kg; ? BMI 10.4 kg/m2), DJBL (? HbA1c, -1.4%, ? bw 22.9 kg; ? BMI 8.8 kg/m2).

These data show that EndoBarrier, specifically designed to mimic the duodenal-jejunal exclusion created by gastric bypass surgery, has a significant impact on glucose homeostasis at one, three and nine months of therapy, which can reduce the reliance patients may have on diabetes medications.

GI Dynamics is the developer of EndoBarrier, the first endoscopically-delivered device therapy approved for the treatment of obese type 2 diabetes with BMI >= 30 kg/m2, or obese patients with BMI >= 30 kg/m2 with >= 1 comorbidities, or obese patients with BMI >35 kg/m2.

The liner is indicated for a maximum implant duration of 12 months. EndoBarrier is approved and commercially available in multiple countries outside the US EndoBarrier is not approved for sale in the US and is limited by federal law to investigational use only in the United States.

GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the US for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 19, 2015
Words:383
Previous Article:Direct Flow Medical Reports Positive 2-Year Data for Transcatheter Aortic Heart Valve System.
Next Article:Study Finds Significant Tissue Modification Associated with Orbital Atherectomy Led to Better Stent Apposition, Expansion.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters